The round was led by Cambridge Enterprise, the commercialisation arm of the University of Cambridge, and 24 Haymarket, with key investors Dr Jonathan Milner (Chairman), Providence Investment Company, Parkwalk, and Cambridge Capital Group also participating. This funding follows the closing of £2.28 million ($3.83 million) Series A funding in 2014.
DefiniGEN is focused on serving the growing need in the pharmaceutical industry for more accurate predictions of efficacy and toxicity in drug candidates ahead of clinical trials. Its platform technology OptiDIFF is a revolutionary stem cell production platform for the generation of high-functionality cell types including, liver, pancreatic and lung cells. These cells can be used as predictive in vitro models to support the development of safer and more effective treatments for diseases.
The new funding will help drive DefiniGEN to profitability and enable the Company to achieve the following:
- Delivery of ground-breaking cryopreserved pancreatic beta cell products to the global diabetes drug development market
- Development of lung and intestinal cell products to assist the development of treatments for major genetic diseases, such as cystic fibrosis
- Expansion of business development in North America, Europe, and Asia Pacific with dedicated local marketing presence
- Recruitment of high-quality production staff and invest in up-scaled production at the Company’s enlarged laboratory facilities
- Strengthening of the Company’s intellectual property portfolio
Commenting on the announcement, Dr Marcus Yeo, CEO of DefiniGEN (pictured) said: “In a short space of time, DefiniGEN has undergone rapid development, securing growing sales with global pharma companies. We are delighted to have raised the funds that will allow us to deliver new market-leading products to our customers and assist them in developing therapies for the global healthcare challenges we face today such as diabetes and liver disease.”
Dr Jonathan Milner, Chairman of DefiniGEN and formerly CEO of Abcam Plc, said: “DefiniGEN is harnessing the power of stem cell technology to develop products that are transformational for drug discovery, enabling the accelerated development of therapies that can beneficially transform the lives of afflicted people.”
About DefiniGEN Ltd http://www.definigen.com/
DefiniGEN was founded in 2013 to commercialise OptiDIFF, the stem cell production platform developed at the University of Cambridge, UK. The Company has world-leading expertise in the area of iPSC-derived human cell production and metabolic disease modelling. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products enabling the development of safer and more effective treatments. In addition, the technology platform utilises fully defined and humanised conditions required for the development of regenerative medicine cellular therapies. DefiniGEN builds on intellectual property and knowledge resident at the University of Cambridge Regenerative Medicine Department at Addenbrooke’s Hospital and has in-licensed the Yamanka induced pluripotent stem cell IP portfolio from iPS Academia Japan Inc.
*******
Media Contact:
Maree Devine, Zyme Communications Ltd
Email: maree.devine@zymecommunications.com
Phone: +44 (0) 7788 214 531
_____________________________________________________